TherapeuticsMD Receives a Buy from Noble Financial

By Austin Angelo

In a report released yesterday, Caroline Palomeque from Noble Financial reiterated a Buy rating on TherapeuticsMD (NYSE MKT: TXMD). The company’s shares closed yesterday at $6.04.

According to, Palomeque is ranked 0 out of 5 stars with an average return of -12.8% and a 40.9% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Adamas Pharmaceuticals, and Corbus Pharmaceuticals.

Currently, the analyst consensus on TherapeuticsMD is Strong Buy and the average price target is $16.33, representing a 170.4% upside.

In a report issued on December 19, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $28 price target.

The company has a one-year high of $8.30 and a one-year low of $3.50. Currently, TherapeuticsMD has an average volume of 3.45M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TherapeuticsMD, Inc. is a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.